Format
Sort by

Send to

Choose Destination

Search results

Items: 19

1.

Abnormalities of the glutamine-glutamate-GABA cycle in the schizophrenia brain.

Hashimoto K.

Schizophr Res. 2014 Jul;156(2-3):281-2. doi: 10.1016/j.schres.2014.04.008. Epub 2014 May 5. No abstract available.

PMID:
24811432
2.

Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings.

Poels EM, Kegeles LS, Kantrowitz JT, Javitt DC, Lieberman JA, Abi-Dargham A, Girgis RR.

Schizophr Res. 2014 Feb;152(2-3):325-32. doi: 10.1016/j.schres.2013.12.013. Epub 2014 Jan 11. Review.

3.

Increased glutamine in patients undergoing long-term treatment for schizophrenia: a proton magnetic resonance spectroscopy study at 3 T.

Bustillo JR, Chen H, Jones T, Lemke N, Abbott C, Qualls C, Canive J, Gasparovic C.

JAMA Psychiatry. 2014 Mar;71(3):265-72. doi: 10.1001/jamapsychiatry.2013.3939.

PMID:
24402128
4.
5.

Brain metabolite alterations in young adults at familial high risk for schizophrenia using proton magnetic resonance spectroscopy.

Tandon N, Bolo NR, Sanghavi K, Mathew IT, Francis AN, Stanley JA, Keshavan MS.

Schizophr Res. 2013 Aug;148(1-3):59-66. doi: 10.1016/j.schres.2013.05.024. Epub 2013 Jun 20.

PMID:
23791389
6.

Proton magnetic resonance spectroscopy of the substantia nigra in schizophrenia.

Reid MA, Kraguljac NV, Avsar KB, White DM, den Hollander JA, Lahti AC.

Schizophr Res. 2013 Jul;147(2-3):348-54. doi: 10.1016/j.schres.2013.04.036. Epub 2013 May 21.

7.

Multimodal analysis of the hippocampus in schizophrenia using proton magnetic resonance spectroscopy and functional magnetic resonance imaging.

Hutcheson NL, Reid MA, White DM, Kraguljac NV, Avsar KB, Bolding MS, Knowlton RC, den Hollander JA, Lahti AC.

Schizophr Res. 2012 Sep;140(1-3):136-42. doi: 10.1016/j.schres.2012.06.039. Epub 2012 Jul 23.

8.

Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla.

Bustillo JR, Chen H, Gasparovic C, Mullins P, Caprihan A, Qualls C, Apfeldorf W, Lauriello J, Posse S.

Biol Psychiatry. 2011 Jan 1;69(1):19-27. doi: 10.1016/j.biopsych.2010.08.024. Epub 2010 Oct 20.

9.

Thalamic neurochemical abnormalities in individuals with prodromal symptoms of schizophrenia - relationship to auditory event-related potentials.

Stone JM, Bramon E, Pauls A, Sumich A, McGuire PK.

Psychiatry Res. 2010 Aug 30;183(2):174-6. doi: 10.1016/j.pscychresns.2010.05.004.

PMID:
20620033
10.

1H-MRS at 4 tesla in minimally treated early schizophrenia.

Bustillo JR, Rowland LM, Mullins P, Jung R, Chen H, Qualls C, Hammond R, Brooks WM, Lauriello J.

Mol Psychiatry. 2010 Jun;15(6):629-36. doi: 10.1038/mp.2009.121. Epub 2009 Nov 17.

11.

Striatal metabolic alterations in non-psychotic adolescent offspring at risk for schizophrenia: a (1)H spectroscopy study.

Keshavan MS, Dick RM, Diwadkar VA, Montrose DM, Prasad KM, Stanley JA.

Schizophr Res. 2009 Nov;115(1):88-93. doi: 10.1016/j.schres.2009.08.012. Epub 2009 Sep 11.

PMID:
19748228
12.

Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume.

Stone JM, Day F, Tsagaraki H, Valli I, McLean MA, Lythgoe DJ, O'Gorman RL, Barker GJ, McGuire PK; OASIS.

Biol Psychiatry. 2009 Sep 15;66(6):533-9. doi: 10.1016/j.biopsych.2009.05.006. Epub 2009 Jun 25.

PMID:
19559402
13.

Glutaminase-deficient mice display hippocampal hypoactivity, insensitivity to pro-psychotic drugs and potentiated latent inhibition: relevance to schizophrenia.

Gaisler-Salomon I, Miller GM, Chuhma N, Lee S, Zhang H, Ghoddoussi F, Lewandowski N, Fairhurst S, Wang Y, Conjard-Duplany A, Masson J, Balsam P, Hen R, Arancio O, Galloway MP, Moore HM, Small SA, Rayport S.

Neuropsychopharmacology. 2009 Sep;34(10):2305-22. doi: 10.1038/npp.2009.58. Epub 2009 Jun 10.

14.

Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS).

Tayoshi S, Sumitani S, Taniguchi K, Shibuya-Tayoshi S, Numata S, Iga J, Nakataki M, Ueno S, Harada M, Ohmori T.

Schizophr Res. 2009 Mar;108(1-3):69-77. doi: 10.1016/j.schres.2008.11.014. Epub 2008 Dec 20.

PMID:
19097753
15.

Brain metabolite abnormalities in the white matter of elderly schizophrenic subjects: implication for glial dysfunction.

Chang L, Friedman J, Ernst T, Zhong K, Tsopelas ND, Davis K.

Biol Psychiatry. 2007 Dec 15;62(12):1396-404. Epub 2007 Aug 13.

16.

What have we learned from proton magnetic resonance spectroscopy about schizophrenia? A critical update.

Abbott C, Bustillo J.

Curr Opin Psychiatry. 2006 Mar;19(2):135-9. Review.

PMID:
16612192
17.

Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study.

Ohrmann P, Siegmund A, Suslow T, Spitzberg K, Kersting A, Arolt V, Heindel W, Pfleiderer B.

Schizophr Res. 2005 Mar 1;73(2-3):153-7.

PMID:
15653258
18.

Proton magnetic resonance spectroscopy of the human brain in schizophrenia.

Deicken RF, Johnson C, Pegues M.

Rev Neurosci. 2000;11(2-3):147-58. Review.

PMID:
10718151
19.

Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy.

Bartha R, Williamson PC, Drost DJ, Malla A, Carr TJ, Cortese L, Canaran G, Rylett RJ, Neufeld RW.

Arch Gen Psychiatry. 1997 Oct;54(10):959-65.

PMID:
9337777
Items per page

Supplemental Content

Loading ...
Write to the Help Desk